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Abstract
Immunological adjuvants, such as bacterial LPS, increase the mRNA levels of the IkB-related NF-kB
transcriptional transactivator, Bcl-3, in activated T cells. Adjuvants also increase the life expectancy
of activated T cells, as does over-expression of Bcl-3, suggesting that Bcl-3 is part of the pathway
whereby adjuvants affect T cell lifespans. However, previous reports, conﬁrmed here, show that
adjuvants also increase the life expectancies of Bcl-3-deﬁcient T cells, making Bcl-3’s role and effects
in adjuvant-induced survival uncertain. To investigate the functions of Bcl-3 further, here we conﬁrm
the adjuvant-induced expression of Bcl-3 mRNA and show Bcl-3 induction at the protein level. Bcl-3
was expressed in mice via a transgene driven by the human CD2 promoter. Like other protective
events, over-expression of Bcl-3 slows T cell activation very early in T cell responses to antigen, both
in vitro and in vivo. This property was intrinsic to the T cells over-expressing the Bcl-3 and did not
require Bcl-3 expression by other cells such as antigen-presenting cells.
Introduction
Vaccines are important contributors to human and animal
health. For many years, it has been appreciated that suc-
cessful vaccines must contain not only an antigen, a compo-
nent of the target infectious agent, but also an adjuvant,
a material that improves the primary immune response and
essential for the creation of good immunological memory
(1–5). We and others have shown that one effect of adju-
vants is to increase the numbers and survival of antigen-
speciﬁc memory cells (6, 7).
In efforts to understand how adjuvants affect the creation
of memory cells, some years ago we compared gene ex-
pression in T cells responding to antigen in the presence or
absence of adjuvants, in this case, LPS or a bystander viral
infection. We found that a common feature increased Bcl-3
mRNA in the activated T cells that had been stimulated in
the presence of an adjuvant (8, 9). Since then, others have
conﬁrmed this observation and shown that adjuvants proba-
bly raise Bcl-3 levels in T cells via IL-12 produced by the an-
tigen-presenting cells that are the direct targets of the
adjuvants themselves (10–14). Levels of Bcl-3 in the cell
may be controlled both by gene transcription and also by
turnover of the protein itself since a splice variant of the
deubiquitinylating enzyme, CYLD, increases the amount of
Bcl-3 in the cell and increases cell survival (15).
Bcl-3 is a member of the NF-jB family, originally identiﬁed
as a component of a chromosomal rearrangement in some
B cell lymphomas (16) and is over-expressed in activated
human Tcells (17). Bcl-3 is thought to act as a transcriptional
enhancer for NF-jB p50 dimers, which lack a transactivation
domain of their own (18–20) and may also affect transcrip-
tion via its binding to other proteins such as pirin (21, 22).
Bcl-3 may also have effects in the cytoplasm, however, since
it is sometimes found in this part of the cell and is affected
by plasma membrane proximal tyrosine kinases such as
Fyn, Lck and GSK3 (23–25).
To understand more about the effects of Bcl-3 on Tcells, we
compared the activation and survival of Tcells lacking Bcl-3 or
over-expressing the gene. Here we show that over-expression
of Bcl-3 protects both naive and activated T cells from death.
However, surprisingly, adjuvants continue to enhance the sur-
vival of activated T cells, even if Bcl-3 is absent, a result that
conﬁrms a previous observation by others in a similar system
(26). Thus, although Bcl-3 can mimic the effects of adjuvants,
it is not essential for their action on T cells. The experiments
also followed up on the observation that adjuvants often in-
hibit T cell proliferation, to some extent. Bcl-3 over-expression
has the same effect. The experiments showed that Bcl-3 has
this effect very early in the T cell response.
Materials and methods
Mice
C57BL/6J (B6), C57B/6.PLJ (B6.PL), C57Bl/6.SJL (CD45.1)
(B6.SJL), OT1 and Rag1/ mice were purchased from
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crossed to derive OT1 mice expressing Thy1.1 or CD45.1
and lacking Rag1. Mouse Bcl-3 (mBcl-3) cDNA was cloned
into a plasmid in which expression was driven by the human
CD2 promoter (27) and injected into fertilized single-cell
C57BL/6 embryos. Mice were screened for presence of the
Bcl-3 transgene by PCR of tail DNA. Of four transgenic mice
derived from this procedure, one line, named here Bcl-3 Tg,
was selected for further study based on their high expres-
sion of mBcl-3. Bcl-3/ mice were the generous gift of
Ulrich Siebenlist (28). Mice were housed in the National
Jewish Medical and Research Center Animal Care Facility in
accordance with institutional guidelines.
Antibodies
Antibodies bound to the ﬂuorochromes FITC, PE or PerCP
against TCRb (H57-H597), CD4 (GK1.5), CD8a (53-6.7),
CD25 (PC-61), CD44 (IM7), CD62L (MEL-14), CD69
(H1.2F3), CD127 (SB/199), NK1.1 (PK136), 35Vb2 (B20.6),
Vb6 (RR4-7), Vb8 (F23.1) and Thy1.1 (OX-7) were pur-
chased from BD PharMingen (San Diego, CA, USA). Anti-
Vb8 (F23.1), CD45.1 (A20) and Thy1.2 (53-2.1) were puriﬁed
and coupled to biotin by standard methods. Secondary
western blot antibodies, against Igs of various species,
chemically coupled to HRP were purchased from Jackson
ImmunoResearch. These included donkey anti-mouse Ig–HRP,
donkey anti-goat Ig–HRP and goat anti-Armenian hamster
Ig–HRP. mAbs against Bcl-3 were prepared as described
below.
Preparation of anti-mouse Bcl-3 mAb
The cDNA for mBcl-3 was obtained from pGEM4Z-Bcl-3
(29), given a 6His tag and cloned into baculovirus by stan-
dard methods. Bcl-3 was expressed in Hi5 cells and isolated
on Ni-NTA beads yielding a protein of ;64 kD on 10–15%
polyacrylamide gradient gels. Armenian hamsters were im-
munized with 50 lg of the protein in CFA followed by a sec-
ond and third immunization with 20 lg in incomplete
Freund’s adjuvant. The hamster with the highest titer of anti-
Bcl-3 antibody was rested for 4 weeks, injected with 50 lg
soluble Bcl-3 intra-peritoneally and fused 3 days later.
Hybridomas were screened for anti-Bcl-3 antibody by ELISA
using the baculovirus protein as antigen. Positive hybrido-
mas were grown up, cloned and retested by ELISA and
western blot. Of four hybridoma antibodies that detected
mBcl-3 by ELISA and western blot, one, Ham150-3.5 (IgG1
lambda), was chosen for further experiments. Ham150-3.5
reacts also with human Bcl-3 on western blots. Anti-Bcl-3
mAbs were puriﬁed on protein G sepharose beads.
SDS–PAGE western blotting
Cell lysates were prepared in the usual manner. Brieﬂy, cells
were spun in a microfuge for 5 min at 3500 r.p.m. Cell
extracts were made by re-suspending the cell pellet in 13
PBS and adding one-fourth volume of 43 SDS-based load-
ing buffer (NuPage LDS Sample Buffer, Invitrogen, Carlsbad,
CA, USA) followed by shearing through 20 guage needle.
Alternatively, nuclear and cytoplasmic extracts were made
as previously described (30). Brieﬂy, cell pellets were re-
suspended in four times pellet volume of hypotonic buffer
and incubated on ice for 15 min. Then 1/16th volume of
10% NP-40 detergent was added and the mixture was im-
mediately vortexed for 10 s to lyse cells. Then, lysates were
spun at 15 000 3 g for 20 min at 4 C in a microcentrifuge,
and the cytoplasmic supernatant fraction was mixed with
43 loading buffer and incubated for 5 min at 95 C. The pel-
leted nuclei were re-suspended in four volumes of high salt
extraction buffer, rotated for 15 min at 4 C and then spun at
15 000 3 g for 20 min at 4 C in a microcentrifuge. This nu-
clear fraction supernatant was mixed with 43 SDS-loading
buffer and incubated for 5 min at 100 C. Cell lysates were
loaded into 12% or 4–12% gradient Bis/Tris acrylamide gels
(Invitrogen). These gels were run for 2–3 h at 120 volts. The
gels were removed, equilibrated in 15% methanol transfer
buffer and then transferred to polyvinyldiﬂuoride membranes
using a mini wet transfer apparatus (Invitrogen). The transfer
was run at 25 volts for 2 h. The membrane was then re-
moved and washed with Tris-buffered saline with 0.01%
Tween-20 detergent (TBST). Western blotting membranes
were incubated in a blocking solution of 5% weight to vol-
ume of non-fat dry milk in TBST for 1–2 h at 25 C or over-
night at 4 C. Antibodies were diluted in blocking solution to
an empirically optimized dilution depending on the antibody
and allowed to mix for at least 15 min prior to being used.
Membranes were then transferred into the primary antibody
solution and incubated for 1–2 h at 25 C or overnight at
4 C. Blots were then removed, rinsed once in TBST and then
washed in TBST three times for 5–15 minutes per wash. Sec-
ondary antibodies were diluted 1:20,000 in TBST and
allowed to mix for 30 min prior to use. The membranes were
then incubated in secondary antibody for 30–60 min at 25 C
and then washed in TBST as described above. The blots
were developed with ECL-Plus reagent (Amersham) and ex-
posed on Hyperﬁlm (Amersham).
T cell puriﬁcation
To isolate T cells from mice, spleen and lymph nodes (LNs)
(inguinal, brachial, axillary, cervical, mesenteric and peri-
aortic) were dissected from the mouse. The organs were
crushed in 100-lm cell strainers (Falcon, Franklin Lakes, NJ,
USA) with a 5-ml syringe plunger and washed with balanced
salt solution (BSS) to isolate single-cell suspensions. The
cells were spun and RBCs were removed by lysis with
150 mM ammonium chloride for 30 s, spun and washed one
more time with BSS. The cell pellets were re-suspended in 3
ml BSS supplemented with 5% fetal bovine serum (BSS/
FBS). Sterile nylon wool columns were pre-equilibrated with
BSS/FBS at 37 C. Nylon wool columns were allowed to drain
out and then cells were added and allowed to enter the col-
umn. Once in the column, the ﬂow was stopped and the col-
umn (with cells) was incubated for 20 min at 37 C. After
incubation, another 3 ml of BSS/FBS was added and
allowed to enter the column. Once again, the ﬂow was stop-
ped and column was incubated for 20 min at 37 C. The
non-adherent T cells were then washed out with two column
volumes of BSS/5% FBS. This yielded a cell preparation of
85–90% T cells. To increase the purity further, the cells were
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(Miltenyi, Auburn, CA) or by FACS using the MoFLO Cell
Sorter (Cytomation, Fort Collins, CO, USA). Magnetic cell
sorting was done according to the manufacturer’s protocol,
using the AutoMACS system. Brieﬂy, 10
8 cells were incu-
bated with PE anti-Vb8 antibody for 30 min to 1 h at 4 C.
The cells were then washed once with BSS and incubated
for 20 min at 4 C with 100 ll anti-PE Miltenyi beads. These
were then washed a ﬁnal time with BSS and brought up in
3-ml volume. This was loaded onto the AutoMACS machine
and the ‘Poseld’ program was run, collecting both the posi-
tive and negative fractions. Cells thus puriﬁed were typically
95% T cells, as determined by ﬂow cytometry. MoFLO sort-
ing was done by incubating cells with the appropriate stain-
ing antibodies, usually Alexa488–anti-Vb8, PE–anti-CD8,
cychrome–anti-CD4 and allophycocyanin–anti-MHC II. For
staining, cells were brought to 10
8 ml
1 and incubated with
antibodies at 4 C for 60 min in BSS with 20% anti-CD32/64
(2.4G2) supernatant to block Fc receptors. Cells were then
washed with BSS, re-suspended in BSS to 4 3 10
7 cells per
milliliters and run on the MoFLO Cell Sorter. Non-MHC II-
expressing live cells were gated and the resulting cells were
sorted for CD4+Vb8+ or CD8+Vb8+ T cells. These cells were
collected and analyzed for purity on the FacsCaliber (Becton
Dickson, Mountain View, CA, USA) cytometer with generally
>97% T cell purity.
T cell culture and activation
T cells isolated as described were cultured at 37 C in 10%
CO2 in SMEM medium (Invitrogen) supplemented with 10%
FCS (hereafter called CTM). Six-well plates were coated for
24 h at 4 C with anti-CD3 mAb 145-2C11. Plates were then
washed with PBS or BSS, and T cells re-suspended in CTM
and placed in the incubator for desired length of experiment.
CFSE labeling was performed as previously described (31).
Real-time PCR
Total cellular RNA was isolated from cell populations using
either Trizol reagent (Invitrogen) or RNAeasy (Qiagen, Valen-
cia, CA, USA) according to manufacturers’ protocols. Typical
yields were 1.0 lg1 0
6 cells. To make cDNA from mRNA,
Superscript II RT (Stratagene, La Jolla, CA, USA) reverse
transcriptase was used with random hexamer primers for 1
ha t4 2  C. Total RNA was used at 2 lg for a ﬁnal volume of
20 ll. The reaction was stopped by 10 min incubation at
95 C. Real-time quantitative ﬂuorometric PCR was used to
quantify mRNA levels in various cell populations. All reac-
tions were performed on the ABI Prism 7700 sequence de-
tection system (Applied Biosystems, Norwalk, CT, USA)
according to the manufacturer’s directions. The quantity of
the mRNA under analysis was measured using speciﬁc
primer sets for each message and normalized to b-actin
control mRNA. Each set of primers was designed using
Primer Express (Applied Biosystems) and included three
DNA primers: forward, reverse and a ﬂuorogenic probe. The
ﬂuorogenic probes were coupled to the ﬂuorescent mole-
cules FAM on the 5# end and TAMRA on the 3# end (Synthe-
gene, Houston, TX, USA). Primers used to detect Bcl-3 were
forward primer, 5#-GCGAAGTAGACGTCCATAACAACC-3#;
reverse primer, 5#-ACCAAGAGCCGGACCATGT-3#; FAM–
TAMRA–ﬂuorogenic probe: 5#-CACCTGGCTGTCATCACCA-
CATTACCA-3#.
Results
Adjuvants inhibit the death of antigen-activated T cells and
increase T cell levels of Bcl-3 mRNA and protein
We and others have previously shown that adjuvants inhibit
the rapid deaths in vivo and in vitro of T cells responding to
antigen (6–8, 32). An example of this phenomenon is shown
in Fig. 1(A). In this experiment, T cells bearing Vb8 were acti-
vated with the Vb8-speciﬁc superantigen (Sag), staphylo-
coccal enterotoxin B (SEB), in vivo. One group of animals
received the adjuvant, LPS, 1 day later. One–four days after
the SEB administration, spleen cells were isolated from the
animals, cultured alone for 24 h and the percentage of Vb8+
CD4 and CD8 T cells then evaluated. T cells isolated from
animals 1 day after SEB injection survived well in culture.
However, T cells isolated at a later time died rapidly. Acti-
vated T cell death was inhibited if the mice had been given
LPS 1–2 days previously, but the inhibitory effects of adju-
vant were no longer apparent 4 days after SEB/3 days after
LPS administration.
The effects of adjuvant are correlated with induction of the
Bcl-3 gene (8, 9, 13, 14). Bcl-3 mRNA is readily measurable;
however, in the past, it has been difﬁcult to measure Bcl-3
protein. To deal with this problem, we produced histidine-
tagged Bcl-3 protein in insect cells, used the protein to
immunize Armenian hamsters and produced a hybridoma-
secreting mAb speciﬁc for Bcl-3. The speciﬁcity of the anti-
body was established by its ability to western blot a protein of
molecular weight ;63 kD (Fig. 1C) and by the fact that it did
not react with proteins in T cells of Bcl-3/ mice (Fig. 3C).
As shown in Fig. 1(B) and as previously reported (8, 9,
13), antigen-activated T cells from animals given LPS contain
considerably more Bcl-3 mRNA, measured by real-time
PCR, than do T cells activated without adjuvant. This in-
crease is reﬂected in an increase in the amount of Bcl-3 pro-
tein, with T cells 2 days after Sag activation containing ;4
times more Bcl-3 protein if they had been exposed to LPS
than those activated without adjuvant. Even 3 days after an-
tigen plus LPS, the activated cells contained some Bcl-3
protein, although such protein was not apparent in cells acti-
vated without LPS (Fig. 1C).
Bcl-3 has been reported to be usually located in the nu-
cleus, with some protein found in the cytoplasm. To ﬁnd
the location of the induced Bcl-3 in T cells, cells were acti-
vated in vivo with SEB, with or without LPS 1 day later, and
puriﬁed at various times thereafter by high-speed sorting.
Nuclear and cytoplasmic fractions of the cells were pre-
pared, run on SDS–PAGE and blotted with anti-Bcl-3 and
anti-USF1 (a nuclear marker) or anti-actin (Fig. 2). In the
absence of adjuvant, the amounts of Bcl-3 in the nuclei of
CD4 T cells increased 1 day after activation and remained
elevated to the same extent at days 2 and 3. Bcl-3 was
barely detectable in the cytoplasms of the same cells. If
the CD4 cells were isolated from animals given SEB and
LPS, however, the amounts of Bcl-3 were further increased.
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levels of Bcl-3 elevated 2 and 3 days after activation if the
cells had also been exposed to LPS. Interestingly, two
forms of Bcl-3 (33) were apparent, particularly in the CD8
T cells.
Thus, exposure to adjuvant increases both the mRNA and
the protein levels of Bcl-3 in activated T cells.
Production of Bcl-3 transgenic mice and expression of Bcl-3
in their T cells
To study the effects of Bcl-3 on T cells, we decided to pro-
duce Bcl-3 transgenic mice. Preliminary experiments using
the proximal or distal Lck promoter failed and no increase in
Bcl-3 mRNA or protein was detected in the T cells of mice
transgenic for Bcl-3 driven by these promoters was detected
Fig. 1. Bcl-3 mRNA and protein are increased in Tcells activated in the presence of an adjuvant. Vb8 Tcells were isolated from mice given SEB
with or without LPS 1 day later. (A) Tcells were puriﬁed from the mice at various times after SEB/LPS injection and cultured without added factors.
The percentage of Vb8+ CD4 and CD8 cells that were dead was measured by ﬂow cytometry. Results shown are representative of four
independent experiments. (B) Vb8+ Tcells were isolated 48 h after mice were given SEB with or without LPS 24 h later. Real-time PCR was used
to measure levels of Bcl-3 and actin mRNA. Results shown are typical of four independent experiments. (C) Mice were immunized with SEB with
or without LPS 1 day later. Vb8+ Tcells were isolated from the mice on various days after SEB administration and western blotted for their content
of Bcl-3 and actin. Each lane contained lysates from 2 3 10
5 cells.
Fig. 2. Administration of LPS in vivo increases the level of Bcl-3 protein expressed in activated T cells. Vb8 T cells were activated in vivo as in
Fig. 1(C) and activated CD4 and CD8 cells were puriﬁed by high-speed cell sorting. Nuclear (A) and cytoplasmic (B) fractions were prepared
and western blotted for Bcl-3 and USF1 (A) and Bcl-3 and actin (B). Each lane contains lysates from 5 3 10
5 cells. Numbers represent the ratio of
intensity of the Bcl-3 versus USF1 or actin bands.
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more successful. A transgene was constructed in which
mBcl-3 was driven by the human CD2 promoter (Fig. 3A).
Plasmid coding for this construct was injected into fertilized
B6 eggs and the mice produced screened by PCR of tail
DNA for the presence of the transgene. A single line was
established which over-expressed Bcl-3 protein in T cells at
detectable levels (Bcl-3 Tg). Flow cytometry experiments
showed that the thymuses, spleens and LNs of the Bcl-3 Tg
mice had normal contents of thymocyte, T cell and B cell
populations. There was no evidence that over-expression of
Bcl-3 inhibited self-tolerance, induced by mouse mammary
tumor virus Sags (34) (data not shown).
Naive CD4 and CD8 T cells from Bcl-3 Tg mice expressed
7- to 20-fold more Bcl-3 mRNA than naive T cells from nor-
mal B6 mice did (Fig. 3B). Likewise, naive T cells from Bcl-3
Tg mice expressed more Bcl-3 protein than B6 mice did
(Fig. 3C).
Bcl-3 over-expression protects activated T cells from death,
but is not required for the protective effects of adjuvant
To measure the effects of Bcl-3 over-expression on activated
T cell survival, B6, Bcl-3 Tg and Bcl-3/ mice were given
SEB. One day later, groups of each type of mice were given
LPS, and one day after this, the animals were sacriﬁced,
T cells were isolated from their LN and spleen and cultured
for 24 h. At this point, ﬂow cytometry was used to evaluate
the percentages of activated Vb8+ T cells from each type of
mouse that were alive.
As expected, most of the CD4 and CD8 Vb8 T cells from
B6 mice were dead. Fewer of these cells died if they had
come from B6 mice given both SEB and LPS (Fig. 4A). Acti-
vated T cells from Bcl-3 Tg mice given just SEB died less
readily than similar cells from B6 mice. However, prior ad-
ministration of LPS protected the cells from death still further.
SEB-activated T cells from Bcl-3/ animals also died at
about the same rates as their counterparts from B6 animals.
As noted by others (26), LPS prevented the deaths of Bcl-
3/ activated T cells just as effectively as it prevented
the deaths of wild-type B6 cells (Fig. 4A). Likewise, over-
expression of Bcl-3, as previously reported (8–14), protected
the activated T cells from death. This is probably not due to
the effects of Bcl-3 transgenic expression during develop-
ment of the cells, since similar pro-survival effects of Bcl-3
have been described when the protein is expressed in tran-
sient transduction experiments (8).
Somewhat surprisingly, LPS improved the already quite
good survival of the activated Bcl-3 Tg cells (Fig. 4A). This
could have been either due to increased expression of en-
dogenous Bcl-3 induced by the LPS (as illustrated in Fig. 2)
or due to some other Bcl-3-independent effect of the LPS.
The latter idea is supported by the fact that LPS administra-
tion improved the survival of activated T cells that lacked
Bcl-3 (Fig. 4A) (26). Thus, although Bcl-3 is protective and
Bcl-3 is induced by LPS, the protective effects of LPS do
not require Bcl-3, and some pathway in addition to that
downstream of Bcl-3 may be involved in the effects of adju-
vants on T cell survival. The experiments described here do
not reveal whether or not the protective effects of adjuvants
on normal cells depend mainly on the Bcl-3 pathway or on
the other route.
Bcl-3 over-expression prolongs the survival in vitro of naive
T cells
Bcl-3 protein is barely detectable in naive T cells from nor-
mal animals (Figs 1C and 2); however, the protein is evident
in naive T cells from the Bcl-3 Tg mice (Fig. 3C). To ﬁnd out
if this expression affected the survival of the cells, we iso-
lated spleen cells from normal B6 and Bcl-3 Tg mice and
cultured the cells. At zero time and at various times
Fig. 3. Production of a transgenic mouse line over-expressing Bcl-3 in Tcells. (A) Structure of a plasmid coding for mBcl-3 driven by the human
CD2 promoter. The plasmid was injected into the fertilized eggs of C57BL/6 mice. (B) CD4+ and CD8+ Tcells were isolated from the spleens and
LNs of normal B6 and Bcl-3 Tg mice. RNA was puriﬁed from the cells and real-time PCR used to measure the amount of mBcl-3 mRNA by
comparisonwithactininthecells.(C)TcellswerepuriﬁedfromnaiveB6,Bcl-3knockoutor Bcl-3 Tg mice. Whole-cell lysates were western blotted
for Bcl-3 protein (5 3 10
6 cells per lane) or for actin (3.5 3 10
6 cells per lane). Results shown are typical of two independent experiments.
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levels of CD44) CD4 and CD8 T cells was evaluated. The
results are shown in Fig. 4(B). Both CD4 and CD8 naive
T cells from Bcl-3 Tg mice survived better in vitro than cells
from B6 animals did. Thus, over-expression of Bcl-3 protects
not only activated but also naive T cells from death.
Bcl-3 over-expression inhibits T cell expansion in response to
antigen in vivo
We and others have noticed that, in spite of the fact that
adjuvants inhibit the deaths of activated T cells, the initial T
cell expansions in response to antigen in vivo are less pro-
found if adjuvants are also present (7). Adjuvants both re-
duce the initial rate and delay the peak of expansion of
such cells. We tested whether Bcl-3 over-expression had
similar effects by immunizing Bcl-3 Tg and control mice
with SEB and following the numbers of Vb8+ Tc e l l sin vivo
over time. There was an indication that the response was
slowed in the Bcl-3 Tg animals, but the results did not
achieve signiﬁcant differences from controls. Therefore, to
do the experiment in a more deﬁnitive way and to eliminate
possible effects of expression of the CD2-driven transgene
in cells other than T cells, we crossed the Bcl-3 Tg mice
with OT1 animals to produce Bcl-3 Tg, OT1+ cells. To allow
efﬁcient discrimination of these T cells from normal OT1
cells, the Bcl-3 Tg+,O T 1 + mice were crossed additionally
with B6.PL (Thy1.1+) animals to give rise to Bcl-3 Tg+,O T 1
Tg+ Thy1.1+ mice. OT1+ RAG/ mice expressing CD45.1
were produced by intercrossing with B6.SJL animals.
Spleen cells from both these animals were mixed and
transferred into normal B6 (Thy1.2+ CD45.2+) mice. One
day later, the animals were given ovalbumin (OVA) peptide,
the peptide antigen for the OT1 TCR, and at various times
thereafter the numbers of OT1 TCR+ T cells of various ori-
gins measured, using antibodies to congenic markers and
variable regions.
The OT1+ T cells expanded well in vivo in response to
this challenge and fell back to baseline by day 6. By con-
trast, the Bcl-3 Tg, OT1 T cells barely expanded at all
(Fig. 5A and B) but nevertheless maintained their ex-
panded numbers, such as they were, between days 2 and
6 of the response, suggesting that the cells that had ex-
panded might have been protected from death. These
results, obtained for the two types of cells responding in
the same mice, showed that the effects of the Bcl-3 Tg
were intrinsic to the T cell expressing the Tg and were not
Fig. 4. Resting and activated T cells over-expressing Bcl-3 are protected from death, but Bcl-3 is not required for adjuvant inhibition of T cell
death. (A) Wild-type (Wt) B6, Bcl-3 Tg or Bcl-3/ mice were injected with SEB with or without LPS, 1 day later. Two days after administration of
SEB, Tcells were isolated from the mice and cultured. The percentage of activated Vb8+ Tcells alive 24 h later was evaluated by ﬂow cytometry.
Results shown are the means and standard errors of triplicate cultures and are representative of three independent experiments. (B) Spleen cells
were isolated from unmanipulated Wt B6 or Bcl-3 Tg mice. The cells were cultured and CD4 CD44
lo and CD8 CD44
lo cells assessed for viability at
various times thereafter. Results shown are the means and standard errors of triplicate cultures and are representative of at least ﬁve similar
independent experiments in which survival of total unstimulated CD4 or CD8 T cells was evaluated.
344 Bcl-3 inhibits T cell activation and deathcaused by effects of the Tg on bystander cells. The result
was not due to competition between the wild-type and
Bcl-3 Tg OT1 cells, since similar results were found when
CSFE-labeled cells were injected into separate animals
(data not shown).
This result could have been caused by reduced prolifera-
tion and then reduced death of the Bcl-3 Tg T cells, a result
suggested by the protective effects of the Bcl-3 Tg in vitro
(Fig. 4A and B). On the other hand, Bcl-3 over-expression
could have been killing T cells as they began to respond to
antigen, protecting them only after the peak of the response
had passed. To ﬁnd out which of these explanations were
correct, we checked the initial rates of proliferation of the
cells by repeating the previous experiment, using this time
OT1+ and Bcl-3 Tg+, OT1+ T cells that had been labeled
with the cell cycle monitor, CFSE. The two types of T cells
were labeled with the dye, transferred to B6 mice, chal-
lenged with OVA peptide or not challenged and harvested
2 days later. Cells in mice that had not received OVA pep-
tide did not divide. However, analysis of the CFSE labeling
of the transferred cells showed that, in the same animals,
the OT1 T cells lacking the Bcl-3 Tg had divided more rap-
idly than their Bcl-3 Tg+ counterparts (Fig. 5C). Thus, the
Bcl-3 Tg inhibited T cell expansion in response to antigen in
vivo. These effects were intrinsic to the T cell involved.
Bcl-3 over-expression inhibits T cell activation in vitro
The in vivo experiment described above showed that the
OT1+ Bcl-3 Tg T cells divided much less rapidly in response
to antigen than the OT1+ RAG T cells did. This result was
most probably due to over-expression of Bcl-3; however, the
two sets of cells were also distinguished by the fact that the
Bcl-3 Tg cells were not deﬁcient in RAG; therefore, some of
them might have expressed a second TCR, a receptor that
does not bind the OVA peptide antigen. This could have
caused slower proliferation of the cells. We think that this lat-
ter explanation is unlikely, since only some of the cells would
be expressing second TCR and the effect on proliferation of
the Bcl-3 Tg cells applies to the whole population (Fig. 5C).
However, to check this possibility directly, we decided to
evaluate the response of Bcl-3 Tg and control T cells in vitro
to anti-CD3. This experiment also gave an opportunity to ﬁnd
out if the defect in the Bcl-3 Tg cells was manifested in vitro
as well as in vivo and also whether or not it occurred very
early in the response, at the time of CD69 expression, for
example.
Spleen cells from B6 and Bcl-3 Tg mice were labeled with
CFSE and cultured on anti-CD3-coated plates for various
lengths of time. The T cells responded by dividing and thus
diluting their levels of CFSE. The Bcl-3 Tg T cells responded
less rapidly than the B6 T cell did, however. Even on day 4
of culture, some of the Bcl-3 Tg T cells had barely gone
through more than two or three rounds of proliferation,
whereas virtually all the B6 T cells had divided more than
six times and completely lost detectable levels of their CFSE
label by this time (Fig. 6A). T cells from B6 and Bcl-3 Tg T
cells express equivalent levels of TCR (data not shown);
therefore, the defect in proliferation of Bcl-3 Tg T cells is not
due to lack of surface TCR. Also, the defect in Bcl-3 Tg T
cells is measurable in vitro.
To ﬁnd out how quickly the effects of Bcl-3 over-
expression were manifested, we checked induction of one
of the earliest markers expressed on T cells when they be-
gin activation, CD69. The OT1+ and Bcl-3 Tg+,O T 1 + T cells
used in previous experiments were mixed together and cul-
tured on plates coated with anti-CD3 antibody. CD69 be-
came apparent on the OT1 cells beginning ;60 min after
the start of culture and increasing in amounts thereafter
Fig. 5. Over-expression of Bcl-3 slows Tcell responses to antigen. (A)
Spleen cells were isolated from mice expressing the OT1 TCR, RAG,
the Bcl-3 Tg and Thy1.1 (Bcl-3 Tg) and from mice expressing the OT1
TCR, deﬁcient in RAG and expressing CD45.1 (Wt). Analysis showed
that the percentage of OT1+ cells in each population was the same
(data not shown). Normal recipients were injected intravenously with
2.5 3 10
6 of an equal mixture of each type of spleen cell. One day
later, the mice were immunized with 10 lg OVA peptide (solid lines) or
untreated (dotted lines). At various times thereafter, LN (A) and spleen
(B) cells were harvested and analyzed for their content of OT1 cells by
congenic marker staining. Results shown are the means and standard
errors of three identically treated mice and are representative of three
independent experiments. (C) Spleen cells from OT1+ Bcl-3 Tg+
Thy1.1+ (Bcl-3 Tg) and OT1+ Bcl-3Tg Tg Thy1.2+ (Wt) mice were
stained with CFSE and transferred as described in (A) and (B). One
day later, recipients were given 10 lg OVA peptide or unimmunized
(dotted lines) and 2 days later the mice were sacriﬁced and the
transferred cells analyzed for dilution of their CFSE label.
Bcl-3 inhibits T cell activation and death 345(Fig. 6B). The Bcl-3 Tg T cells responded by increasing
their surface levels of CD69 too, but less rapidly. Similar
results were obtained with other doses of anti-CD3 anti-
body (Fig. 6C) and also when the two types of cells were
plated separately (data not shown). Thus, Bcl-3 over-
expression reduces the rate of T cell activation, even at
very early stages of the response.
Discussion
Adjuvants affect immune responses via many processes,
with several outcomes. Among these is the fact that adju-
vants increase the likelihood that activated T cells will con-
vert to memory T cells, thus increasing the pool of memory
cells available to defend its host against second infections
by the same organism.
We and others have previously shown that one effect of
adjuvants is to increase expression in cells of the gene for
the IkB-related protein, Bcl-3, a phenomenon that is demon-
strated in this paper in terms of Bcl-3 protein. In previous
publications and here, it has been shown that Bcl-3 over-
expression protects activated T cells from death (8–10, 13).
Therefore, the idea that adjuvants act to promote T cell sur-
vival via induction of Bcl-3 is a natural conclusion to draw.
However, adjuvants affect T cell survival in ways that do not
necessarily involve this protein (35). Thus, the ﬁnding
reported here and elsewhere (Chilton and Mitchell, 2006),
that adjuvants can increase the rates of survival of T cells
lacking Bcl-3, is perhaps not unexpected. This result may
mean that Bcl-3 is not a crucial factor in wild-type T cells and
that the adjuvant-induced expression and survival effects are
merely correlative. On the other hand, it may be that Bcl-3
participates in the creation of memory Tcells in wild-type cells
but that in Bcl-3-deﬁcient cells, some other process has been
called into play to substitute for the absent protein. Such com-
pensatory effects have been observed in many other systems
and may be especially evident for phenomena involving cell
survival, where, of course, cells expressing alternative means
of survival will be well selected.
Fig. 6. Over-expression of Bcl-3 inhibits an early event in T cell activation. (A) T cells from OT1+ Bcl-3 Tg+ Thy1.1+ mice (solid lines) and from
OT1+ Bcl-3 Tg Thy1.2 mice (gray lines) were labeled with CFSE, mixed in equal numbers and cultured on plates coated with 20 mg ml
1 anti-
CD3. At various times thereafter, CFSE dilution of the Tcells was evaluated. (B) Tcells from OT1+ Bcl-3 Tg+ Thy1.1+ mice (solid lines) and from
OT1+ Bcl-3 Tg Thy1.2 mice (gray lines) were mixed in equal numbers and cultured on plates coated with 20 lgm l
1 anti-CD3. At various times
thereafter, CD69 expression by the cells was evaluated. The results for this and a similar experiment in which the anti-CD3 was used at 2 lgm l
1
are summarized in (C). Results shown are representative of three independent experiments.
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increased the survival of naive T cells. This perhaps unex-
pected result is in line with the effects of other rescuing
agents. For example, over-expression of Bcl-2 protects both
resting and activated T cells from death. In vivo, the life ex-
pectancy of both kinds of cells is prolonged by IL-2-related
cytokines(36–39) and such factors are thought to affect lym-
phocyte survival via their induction of anti-apoptotic proteins
like Bcl-2 (40, 41). Although different cytokines affect naive
and activated T cells, this may reﬂect differential expression
of the receptors for the cytokines, rather than dependence
on different intracellular signaling pathways. Nevertheless,
gene array analyses have shown that over-expression of
Bcl-3 does not change the levels of mRNA for Bcl-2-related
proteins (data not shown). Therefore, if the Bcl-3 and IL-2
family pathways for rescuing T cells intersect, Bcl-3 cannot
be affecting Bcl-2 family expression.
It is not clear how Bcl-3 affects T cell survival. Bcl-3 is
unique among most IkB members in containing a transactiva-
tion domain capable of activating transcription for NF-jB
members and many groups have shown that Bcl-3 can bind
and regulate p50 and p52 homodimers (42–44). This sug-
gests a transcriptional regulation of NF-jB targets as a po-
tential mechanism of action of the Bcl-3 protein. The notion
is supported by two other sets of results. First, Bcl-3 and
the transactivation-containing NF-jB protein, p65, act redun-
dantly with each other in supporting the survival of thymus
medullary epithelial cells (45). Second, additional work has
shown that Bcl-3 can control access of the signaling protein,
Bcl-10, to the nucleus (46).
On the other hand, Bcl-3 may have a function that is re-
stricted to the cytoplasm. Previous reports have also sug-
gested that only a small portion of the ankryn repeat domain
of Bcl-3, independent of the transactivation domain, is required
for its ability to prevent apoptosis of activated Tcells (47), sug-
gesting a non-transcriptional mechanism of action. Here we
show that adjuvants increase the level of both nuclear and
cytoplasmic Bcl-3. In this context, it is interesting to note that
preliminary gel shift experiments, not shown here, have not
revealed any clear changes in NF-jB binding to DNA in Bcl-
3 transgenic versus normal T cells, so perhaps a cytoplasmic
function is involved in the effects of the protein.
Most interestingly, here we show that over-expression of
Bcl-3 not only protects T cells from death but also dramati-
cally slows their rates of activation, very early in their
responses. The effect is intrinsic to the T cells themselves
and is not mediated by bystander effects on other cells such
as antigen-presenting cells. This result supports the idea
that Bcl-3 itself is involved in the normal effects of adjuvants
on activated T cells since they, like Bcl-3, both protect the
cells from death and slow their activation. A number of
papers have shown that interference with death processes
is often accompanied by slowed T cell activation. For exam-
ple, T cells lacking the death receptor, Fas, or part of its
signaling cascade proliferate less well (48–50). Likewise,
over-expression of the anti-apoptotic proteins, Bcl-2 or
Bcl-xl, or under-expression of the pro-apoptotic factor, Bim,
delays division of T cells [(51–53), M. Wang and P. Marrack,
unpublished observation]. A recent paper showed that T
cells lacking the executioner proteins, Bax and Bak, fail to
die upon activation and also enter cell cycle slowly. The inhi-
bition of activation was shown to be due to failure to release
Ca++ from intracellular stores (54). However, preliminary
experiments show that Ca++ release is normal after TCR en-
gagement in Bcl-3 over-expressing cells. Thus, reduced
Ca++ ﬂuxes are probably not the cause of the slowed activa-
tion of Bcl-3 Tg T cells.
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BSS balanced salt solution
FBS fetal bovine serum
LN lymph node
mBcl-3 mouse Bcl-3
OVA ovalbumin
Sag superantigen
SEB staphylococcal enterotoxin B
TBST Tris-buffered saline with 0.01% Tween-20 detergent
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